Daniel Long

Dan Long is a highly experienced drug hunter with a track record for leading and participating on high-performing teams that discover drug candidates and advance them through preclinical development to IND and into the clinic. His deep understanding of the drug discovery process has resulted in novel, innovative, and differentiated clinical compounds across a range of diseases.

Dan had a 20-year tenure at Theravance Biopharma where he was most recently VP, Head of Medicinal Chemistry, Biology & Pharmacology. Dan was involved in the nomination of 20 development candidates, eight of which have completed Phase 2 studies to date, including nezulcitinib, an inhaled, lung-selective, pan-JAK inhibitor; axelopran, a peripherally-restricted opioid receptor antagonist; velusetrag, a 5-HT4 receptor agonist; and cefilavancin, a glycopeptide-cephalosporin heterodimer antibiotic.

Dan received his BA, MA and DPhil degrees in Chemistry from the University of Oxford and completed an industrial post-doctoral fellowship at DuPont Pharmaceuticals. Dan has published extensively and is a named inventor on more than 90 patents.